PMID- 37139349
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230505
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 16
DP  - 2023
TI  - Association of Bone Turnover Markers with Type 2 Diabetes Mellitus and 
      Microvascular Complications: A Matched Case-Control Study.
PG  - 1177-1192
LID - 10.2147/DMSO.S400285 [doi]
AB  - PURPOSE: The aim of this study was to evaluate the association of bone turnover 
      markers (BTMs) with type 2 diabetes mellitus (T2DM) and microvascular 
      complications. METHODS: A total of 166 T2DM patients and 166 non-diabetic 
      controls matched by gender and age were enrolled. T2DM patients were 
      sub-classified into groups based on whether they had diabetic peripheral 
      neuropathy (DPN), diabetic retinopathy (DR), and diabetic kidney disease (DKD). 
      Clinical data including demographic characteristics and blood test results [serum 
      levels of osteocalcin (OC), N-terminal propeptide of type 1 procollagen (P1NP), 
      and beta-crosslaps (beta-CTX)] were collected. Logistic regression and restrictive 
      cubic spline curves were performed to examine the association of BTMs with the 
      risk of T2DM and microvascular complications. RESULTS: After adjusting for family 
      history of diabetes, sex and age, an inverse association was observed between 
      elevated serum OC levels [O, p < 0.001] and increased serum P1NP levels , p < 
      0.001] with the risk of T2DM. Moreover, there was an inverse linear association 
      of serum OC and P1NP levels with the risk of T2DM. However, beta-CTX was not 
      associated with T2DM. Further analysis showed a nonlinear association between OC 
      and the risk of DR, while P1NP and beta-CTX were not correlated with DR. Serum 
      concentrations of BTMs were not associated with the risks of DPN and DKD. 
      CONCLUSION: Serum OC and P1NP levels were negatively correlated with T2DM risk. 
      Particularly, serum OC levels were associated with DR risk. Given that BTMs are 
      widely used as markers of bone remodeling, the present finding provides a new 
      perspective for estimating the risk of diabetic microvascular complications.
CI  - (c) 2023 Hou et al.
FAU - Hou, Yilin
AU  - Hou Y
AD  - Graduate School, Hebei Medical University, Shijiazhuang, Hebei, 050017, People's 
      Republic of China.
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, 050051, 
      People's Republic of China.
FAU - Hou, Xiaoyu
AU  - Hou X
AD  - Graduate School, Hebei Medical University, Shijiazhuang, Hebei, 050017, People's 
      Republic of China.
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, 050051, 
      People's Republic of China.
FAU - Nie, Qian
AU  - Nie Q
AUID- ORCID: 0000-0001-5394-2382
AD  - Health Examination Center, Hebei General Hospital, Shijiazhuang, Hebei, 050051, 
      People's Republic of China.
FAU - Xia, Qiuyang
AU  - Xia Q
AD  - Graduate School, Hebei Medical University, Shijiazhuang, Hebei, 050017, People's 
      Republic of China.
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, 050051, 
      People's Republic of China.
FAU - Hu, Rui
AU  - Hu R
AD  - Graduate School, Hebei Medical University, Shijiazhuang, Hebei, 050017, People's 
      Republic of China.
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, 050051, 
      People's Republic of China.
FAU - Yang, Xiaoyue
AU  - Yang X
AD  - Graduate School, Hebei Medical University, Shijiazhuang, Hebei, 050017, People's 
      Republic of China.
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, 050051, 
      People's Republic of China.
FAU - Song, Guangyao
AU  - Song G
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, 050051, 
      People's Republic of China.
AD  - Department of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, 
      050017, People's Republic of China.
FAU - Ren, Luping
AU  - Ren L
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, 050051, 
      People's Republic of China.
AD  - Department of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, 
      050017, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20230426
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC10149773
OTO - NOTNLM
OT  - bone turnover markers
OT  - microvascular complications
OT  - type 2 diabetes mellitus
COIS- The authors report no conflicts of interest in this work.
EDAT- 2023/05/04 06:42
MHDA- 2023/05/04 06:43
PMCR- 2023/04/26
CRDT- 2023/05/04 02:17
PHST- 2022/12/06 00:00 [received]
PHST- 2023/04/12 00:00 [accepted]
PHST- 2023/05/04 06:43 [medline]
PHST- 2023/05/04 06:42 [pubmed]
PHST- 2023/05/04 02:17 [entrez]
PHST- 2023/04/26 00:00 [pmc-release]
AID - 400285 [pii]
AID - 10.2147/DMSO.S400285 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2023 Apr 26;16:1177-1192. doi: 10.2147/DMSO.S400285. 
      eCollection 2023.